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functional class and hematocrit and a significant decrease in aortic periprosthetic
regurgitation.
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Background: Older patients (pts) with aortic valve stenosis suitable for transcatheter
aortic valve implantation (TAVI) have an increased operative risk due to advanced age
and co-morbidities. However current risk scores have been shown not to be the ideal tool
to predict postinterventional outcome in this population. Frailty especially seems to be one
of the major factors not included into these scores. Therefore aim of this study was to
elucidate whether frailty assessment helps to predict outcome after TAVI.
Methods: Pts were assessed prospectively regarding there over all appearance by two
independent physicians and a numerical score from 1 (frail)-10 (good condition) was
given. Additionally Katz activity score, gait speed testing, a five feet walk test and a hand
grip strength test were performed. After 30days follow-up hemodynamic, clinical data as
well as VARC safety endpoints were analysed.
Results: A total of 75pts (age 816years) with a logEuroSCORE of 20.612.7% were
treated. Almost ¾ of the pts received a Medtronic CoreValve and 19 an Edwards SAPIEN
XT, two of them as valve-in-valve. The prostheses were successfully implanted in all pts.
The mean gradient declined from 67.012.3 to 12.07.5mmHg. VARC success was
achieved in 97.3%. The combined safety endpoint occurred in 24%. One pt died due to
intracranial haemorrhage and one major stroke was noted. Thus major stroke and death
occurred in 2.67%. Mean appearance score was 6.31.7, mean Katz activity score
5.41.4. Mean time to overcome five-feet was measured 8.54.2s. Mean hand grip
strength of the dominant hand was 20.28.5Kg. There was no significant predictive value
of hand grip strength and Katz score using a regression analysis (p0.938; 0.925-1.089;
p0.301; 0.526-1.222). The reduced walking speed failed to reach the level of signifi-
cance in this relatively small cohort (p0.06; 0.991-1.529). Only the overall appearance
score had significant predictive value for the occurrence of the combined safety endpoint
(p0.015; 0.280-0.873).
Conclusions: TAVI in older pts with higher risk is safe, feasible and reliable. Frailty
assessment provides additional information but individual clinical judgment remains
crucial to insure beneficial outcome.
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Background: Valve-size selection for TAVI is based on annular measurements by
echocardiography or CT. Still, relevant PAR with negative impact on survival is
common(20%). We sought to evaluate whether supraaortic angiography during BAV may
provide improved sizing(figure).
Methods: Data of 167 consecutive pts with conventional sizing (echo,CT) (group 1) were
compared to 103 successive pts, in which BAV was, additionally leveraged for
size-selection (group 2). PAR was graded angiographically (Sellers criteria) and quanti-
tatively using the pressure difference between diastolic aortic pressure and LVEDP (P
DAP–LVEDP) and the myocardial supply-demand ratio (DPTI:SPTI), a P DAP–
LVEDP18 mmHg and a DPTI:SPTI0.7 having previously been proposed as cut-off
values associated with increased cardiovascular mortality.
Results: TAVI was successful in all pts (ES:166,MCV:103), PAR was observed in
113pts of gp1 and 41pts of gp2 (67vs40%, p0.05). At least Moderate PAR, a p
DAP–LVEDP18 mmHg and a DPTI:SPTI0.7 were observed more frequently in gp1
than gp2: 14.4vs7.8%, 26.3vs14.5% and 11.9vs6.7% (p0.05). According to preinter-
ventional imaging, 40pts had a borderline annulus size, raising uncertainty regarding
valve-size selection. Balloon-sizing resulted in selection of the “bigger” prosthesis in
21pts; only 2 of these pts had relevant PAR. Cardiovascular mortality at 30 days&1-year
was significantly decreased in gp2 compared to gp1 (5.8vs9% & 10.6vs20%, p0.05).(no
BAV-complications).
Conclusions: Preparatory BAV during TAVI can be leveraged to improve valve-size
selection and reduce associated PAR, especially in borderline cases.
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Background: TAVI is currently transforming the treatment of non-operable and
high-risk pts. with aortic stenosis, and the randomized PARTNER trial has shown
excellent results. Notably, several pts. with comorbid conditions, which are frequently
encountered in a real-world setting, were excluded. However, such pts. are already treated
in countries with CE-approval. We report our two-center transfemoral (TF) TAVI-
experience with focus on the comparison between real-world and PARTNER-like
patients.
Methods: Over 6 years (2006-11) 485 pts. (age: 807;EuroSCORE: 2216%) under-
went TF TAVI (ES 176; MCV 309). Patients were divided into a “PARTNER-like” and
a “PARTNER-exclusion” group based on PARTNER B inclusion criteria. Differences in
30-day, 1- and 2-year mortality were assessed.
Results: 213 pts. would have been excluded from PARTNER B, most frequent exclusion
criteria being prior valve surgery (16%), chronic renal failure (14%), severe mitral
regurgitation (11%), reduced LV-EF (9%) and prior PCI (6%). Pts. in the “PARTNER-
exclusion” group had a higher 1- and 2-year mortality than in the “PARTNER-like”
group, and a non-significant trend towards an increased 30-day mortality. Compared to
PARTNER-data, “PARTNER-like” pts. had a slightly higher 30-day, but a markedly
lower 2-year mortality. Interestingly, 2-year mortality was also lower in excluded pts.
despite a two-fold 30-day mortality.
Conclusions: In our real-world experience, 44% of TAVI pts. did not meet PARTNER
inclusion criteria. Although these pts. had a comparatively high early hazard, the late
outcome benefit was, interestingly, better than reported for PARTNER.
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Background: TAVI is currently performed with excellent results by dedicated, multi-
disciplinary heart teams at highly specialized centers. In the real-world, a substantial
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number of patients are seen at smaller, non-specialized hospitals, who are experienced in
cardiac catheterization and are interested to offer TAVI to their patients but lack the
structural requirements and experience. We aimed to assess whether a collaborative
performance of TAVI by external interventional cardiologists together with an experi-
enced TAVI team may offer an opportunity to safely treat these patients, thereby
overcoming the inherent learning curve by so-called “on-site proctoring”.
Methods: 490 patients were treated by TAVI at our university hospital since 2005, 282
using TF access. 41 additional TF-TAVI cases were performed by two external
interventionalists together with our institutional heart team. Procedural safety and
outcome was analyzed and compared to our own TF experiences.
Results: In these 41 patients, TF-TAVI could be performed with procedural, 30-day and
1-year mortality rates of 2, 7 and 10%. These rates are similar to our own most recent
results (last tertile: 1.2, 8 and 12%). 9 procedural complications occurred: 1 wire
perforation with surgical conversion and procedural death, 1 major stroke, 1 coronary
occlusion, 5 major vascular complications, 1 minor stroke. In addition to the procedural
death, the patient with the major stroke and one vascular complication patient with
life-threatening bleeding died within 30 days despite initially successful, interventional
management. The other 4 pts. with vascular complications were treated by covered-stent
implantation and recovered without sequelae, and the coronary occlusion was managed by
immediate stentimplantation. Of note, the amount of vascular complications (12%) was
higher than in our latest patient tertile (7%) but still lower than in our initial tertile (33%).
Conclusions: TF-TAVI can be performed with good results by external interventionalists
in collaboration with an institutional heart team at a specialized TAVI-center. Our
observation also supports the concept of “on-site” proctoring for new TAVI operators,
especially regarding complication management.
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Background: Significant PAR has been shown to occur in 20% of pts. undergoing TAVI
and associatd with increased cardiovascular mortality. Pathophysiologially, this may be
explained by a reduced DPTI:SPTI, which is found in severe aortic stenosis. We sought
to evaluate the already established cut-off value of 0.7 for assessing relevance of PAR.
Methods: Data of 167 consecutive TAVI pts. were analysed (ES: 79, MCV: 88), and
PAR was graded angiographically. DPTI:SPTI was calculated based on planimetric
integration of the diastolic area (diastolic pressure time indexDPTI) and the systolic area
(systolic pressure time indexSPTI) (Fig. A).
Results: PAR was observed in 113 (67%) pts. 89 (78.8%) showed mild, 21 (18.6%)
moderate and 3 (2.7%) moderate-to-severe PAR. Cardiovascular mortality at 30 days and
1-year was significantly increased in pts with moderate/moderate-to-severe PAR com-
pared to those with no/mild PAR (50vs4.5% and 71vs6.9%, p0.05). The already
established cut-off value of 0.7 for DPTI:SPTI could be confirmed as an important
quantitative parameter for prediction of cardiovascular mortality (Fig. B). 18 of the 24 pts.
with moderate/moderate-to-severe PAR had a DPTI:SPTI  0.7.
Conclusions: A DPTI:SPTI 0.7 is highly predictive for cardiovascular mortality in the
assessment of paravalvular PAR after TAVI. Though somewhat complex to calculate
compared to previously proposed parameters (e.g. difference between diastolic aortic and
LV enddiastolic pressure,it is independent from heart rate and reflects myocardial
perfusion impairment, which offers a pathophysiological explanation for the increased
mortality.
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Background: There are several risk-stratification tools for cardiac surgery including
aortic valve replacement, but similar models are lacking for transcatheter aortic valve
replacement (TAVR).
Methods: We retrospectively examined the clinical features and course of 45 patients
who underwent transcatheter aortic valve replacement (TAVR) with the Edwards-Sapien
valve for critical aortic stenosis at our center. All were inoperable for surgical valve
replacement. Hospital length of stay (LOS) was calculated from the date of TAVR to the
date of discharge and was expressed as mean SD. Pre-operative clinical variables were
entered in a Cox-hazard proportional model for LOS. Among these variables, the frailty
index was scored with 1 point assigned for each: serum albumin3.5 mg/dl, in-ability to
independently perform at least 4 of 6 Katz activities of daily living, inability to walk 5
meters in less than 7 sec, and grip strength  18 kg. Patients with  3 points were
considered frail.
Results: The mean LOS for all 45 patients was 9.9  6.9 days. Multivariate predictors
of length of stay are illustrated in the table. A total of 22 (49%) were categorized as frail
as per our index definition. Mean LOS was 12.18.4 days among frail patients vs 7.7 
4.0 days among non-frail patients (p0.029).
Parameter OR OR (95%CI) p value
Age (yrs) 2.071 1.221–3.332 0.005
Frailty 5.910 3.730–10.471 0.015
Pre-operative Hemoglobin (g/dl) 0.048 0.015–0.916 0.041
Pre-operative Creatinine (mg/dl) 0.001 0.000–0.006 0.008
Pre-operative Ejection fraction 1.350 0.796–1.965 0.330
Underlying Moderate –Severe lung
disease
0.178 0.030–1.067 0.059
Conclusions: Our study suggests that frailty is not only a marker for inoperability for
surgical aortic valve replacement, but is also predictive of prolonged recovery among
patients undergoing transcatheter aortic valve replacement for critical aortic stenosis. This
information can be used not only for optimal patient selection but also for counseling
patients about realistic post-operative goals and expectations.
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Background: B-type natriuretic peptide (BNP) is released in response to increased
myocardial wall stress and its levels are known to increase in diastolic and systolic heart
failure. Heart failure related to severe aortic stenosis is expected to improve after valve
replacement. We examined the relationship between BNP and survival after Transcatheter
Aortic Valve Replacement (TAVR).
Methods: We retrospectively reviewed 48 patients who underwent TAVR and had NT
proBNP measured 1 day before (preBNP) and 30 days after TAVR (postBNP). Vital and
clinical status was assessed 1, 6, 12, and 24 months after TAVR. DeltaBNP was
calculated ( postBNP – preBNP). Death from any cause was the primary outcome. We
calculated a hazard ratio (HR) of mortality using the Cox proportional multivariate model.
Results: The median deltaBNP was ()2161 pg/ml (Range: decrease of ()17,481
pg/ml to increase of (	)17,754 pg/ml). This median value divided the patients into those
with (n24) or without (n24) deltaBNP decrease greater than ()2000 pg/ml. PreBNP
did not correlate with survival (p0.264), but a BNP decrease of more than 2000 pg/ml
was strongly associated with survival (HR  0.15, CI (0.05 - 0.49) p0.01); (Figure 1).
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